Fiera Capital Corp Sells 1,635 Shares of Eli Lilly and Company (NYSE:LLY)

Fiera Capital Corp lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,316 shares of the company's stock after selling 1,635 shares during the quarter. Fiera Capital Corp's holdings in Eli Lilly and Company were worth $7,762,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Simon Quick Advisors LLC grew its holdings in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company's stock worth $1,706,000 after purchasing an additional 278 shares during the last quarter. Apexium Financial LP grew its holdings in shares of Eli Lilly and Company by 1,819.1% in the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company's stock worth $6,667,000 after purchasing an additional 10,842 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $363,000. Terril Brothers Inc. grew its holdings in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company's stock worth $471,000 after purchasing an additional 429 shares during the last quarter. Finally, Hartline Investment Corp grew its holdings in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company's stock worth $12,786,000 after purchasing an additional 248 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.1 %

Shares of NYSE:LLY traded down $1.12 during mid-day trading on Friday, reaching $770.00. The stock had a trading volume of 1,652,359 shares, compared to its average volume of 3,013,449. The firm has a market cap of $731.82 billion, a PE ratio of 113.40, a price-to-earnings-growth ratio of 1.56 and a beta of 0.37. The firm has a 50 day simple moving average of $760.66 and a two-hundred day simple moving average of $684.31. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company's revenue for the quarter was up 26.0% on a year-over-year basis. During the same period last year, the company posted $1.62 EPS. On average, research analysts predict that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company's payout ratio is 76.58%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LLY shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a "buy" rating in a research report on Tuesday, April 2nd. Truist Financial upped their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a "buy" rating in a research report on Wednesday, May 1st. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 7th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $769.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.